

Drug Monograph

Drug/Drug **Duobrii™ (halobetasol propionate and tazarotene) topical**
 Class: **lotion / Topical Agents for Psoriasis**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Duobrii is available as a 0.01%/0.045% lotion with each gram containing 0.1 mg halobetasol propionate and 0.45 mg tazarotene. Three package sizes are currently available: 45 g, 60 g and 100 g tubes.

Manufacturer: Manufactured for: Bausch Health Americas, Inc., Bridgewater, NJ 08807

Indications: Duobrii is indicated for the topical treatment of plaque psoriasis in adults.

Costs: \$825.00 per 100-gram tube of Duobrii Lotion 0.1/0.045%. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Non-Preferred
 Appropriate Indications No PA Required

Prepared By: Tyler Woods PharmD
 Date: June 25, 2019